Transgender individuals assigned male at birth who are undergoing hormone therapy as part of their male-to-female (MTF) transition often take feminizing hormones, such as estrogen and anti-androgens, to induce breast development. These hormones help stimulate the growth of breast tissue and promote feminine secondary sexual characteristics.
Estrogen: Estrogen is the primary hormone used in MTF hormone therapy. It helps feminize the body and is responsible for breast development. Estrogen can be administered in various forms, including pills, patches, injections, or sublingual tablets.
Anti-androgens: Anti-androgens are medications that suppress the effects of testosterone, the primary male sex hormone. By reducing testosterone levels, anti-androgens help to block masculine characteristics and allow estrogen to have a greater impact on feminization.
Breast development occurs gradually over time with hormone therapy, and the extent of growth varies from person to person. Factors such as genetics, age, dosage, and duration of hormone therapy can influence the results. It’s important to work with healthcare professionals who specialize in transgender healthcare to determine the appropriate hormone regimen and monitor the progress of breast development.